Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1)
ChemMedChem · 13.03.2026 · 21 (5)
DOI: 10.1002/cmdc.202500958 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift ChemMedChem, online erschienen am 09.03.2026. Verfasst von Camille Richagneux und 1 weiteren Autor:innen. Beteiligte Einrichtung: CMBC, CNRS UMR9187, INSERM U1196, Institut Curie, Université Paris Saclay, Orsay, France. Hauptthemen laut MEDLINE: Myotonic Dystrophy, RNA-Binding Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 218 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Agence Nationale de la Recherche.
Abstract (Originalsprache)
Myotonic dystrophy type 1 (DM1) is caused by expanded CTG repeats, d(CTG) exp , transcribed into toxic r(CUG) exp RNA repeats that sequester splicing regulator MBNL1, leading to its loss‐of‐function. An emerging therapeutic strategy toward DM1 treatment relies on the inhibition of MBNL1 sequestration by using small molecules, oligomers, peptides, engineered proteins, or synthetic oligonucleotides that interact with CUG repeats at the RNA level and/or CTG repeats at the DNA level. This review covers ∼18 years of research in the field of CUG and CTG ligands that were identified or rationally designed as DM1 drug candidates, with an emphasis on their chemical structures, molecular design, RNA‐ or DNA‐binding modes, in vitro affinities and specificities, molecular mechanisms of action, and biological activity in DM1 models.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CMBC, CNRS UMR9187, INSERM U1196, Institut Curie, Université Paris Saclay, Orsay, France.
- LCBPT, CNRS UMR8601, Université Paris Cité, Paris, France.
ORCID-Profile: Anton Granzhan
Förderung
- Agence Nationale de la Recherche
Zitieren
APA
Richagneux, C., & Granzhan, A. (2026). Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1). ChemMedChem, 21(5). https://doi.org/10.1002/cmdc.202500958
Vancouver
Richagneux C, Granzhan A. Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1). ChemMedChem. 2026;21(5). doi:10.1002/cmdc.202500958
BibTeX
@article{Richagneux2026,
author = {Richagneux, Camille and Granzhan, Anton},
title = {Targeting Expanded CUG and CTG Repeats as a Therapeutic Approach for Myotonic Dystrophy Type 1 (DM1)},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {5},
doi = {10.1002/cmdc.202500958}
}
EUVIMED